Relation of Serum Phosphorus Levels to the Incidence of Atrial Fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study)

      High serum phosphorus levels have been linked with vascular calcification and greater cardiovascular morbidity and mortality. We assessed whether serum phosphorus was associated with the atrial fibrillation (AF) incidence in a large community-based cohort in the United States. Our analysis included 14,675 participants (25% black, 45% men) free of AF at baseline (1987 to 1989) and with measurements of fasting serum phosphorus from the Atherosclerosis Risk In Communities (ARIC) study. The incidence of AF was ascertained through the end of 2008 from study visit electrocardiograms, hospitalizations, and death certificates. Cox proportional hazard models were used to estimate the hazard ratios of AF by the serum phosphorus levels, adjusting for potential confounders. During a median follow-up of 19.7 years, we identified 1,656 incident AF cases. Greater serum phosphorus was associated with a greater AF risk: the hazard ratio of AF with a 1-mg/dl increase in serum phosphorus was 1.13 (95% confidence interval 1.02 to 1.26). No significant interaction was seen by race (p = 0.88) or gender (p = 0.51). The risk of AF was increased in association with greater serum phosphorus in those with an estimated glomerular filtration rate of ≥90 ml/min/1.72 m2 but not among those with an estimated glomerular filtration rate of <90 ml/min/1.72 m2. The total corrected calcium levels were not related to AF risk; however, greater levels of the calcium-phosphorus product were associated with greater AF risk. In conclusion, in the present large population-based study, greater levels of serum phosphorus and the related calcium-phosphorus product were associated with a greater incidence of AF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Benjamin E.J.
        • Levy D.
        • Vaziri S.M.
        • D'Agostino R.B.
        • Belanger A.J.
        • Wolf P.A.
        Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study.
        JAMA. 1994; 271: 840-844
        • Alonso A.
        • Agarwal S.K.
        • Soliman E.Z.
        • Ambrose M.
        • Chamberlain A.M.
        • Prineas R.J.
        • Folsom A.R.
        Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk In Communities (ARIC) study.
        Am Heart J. 2009; 158: 111-117
        • Sanoski C.A.
        Prevalence, pathogenesis, and impact of atrial fibrillation.
        Am J Health Syst Pharm. 2010; 67: S11-S16
        • Wang T.J.
        • Parise H.
        • Levy D.
        • D'Agostino Sr., R.B.
        • Wolf P.A.
        • Vasan R.S.
        • Benjamin E.J.
        Obesity and the risk of new-onset atrial fibrillation.
        JAMA. 2004; 292: 2471-2477
        • Alonso A.
        • Lopez F.L.
        • Matsushita K.
        • Loehr L.R.
        • Agarwal S.K.
        • Chen L.Y.
        • Soliman E.Z.
        • Astor B.C.
        • Coresh J.
        Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk In Communities (ARIC) study.
        Circulation. 2011; 123: 2946-2953
        • Tonelli M.
        • Sacks F.
        • Pfeffer M.
        • Gao Z.
        • Curhan G.
        • Cholesterol and Recurrent Events Trial Investigators
        Relation between serum phosphate level and cardiovascular event rate in people with coronary disease.
        Circulation. 2005; 112: 2627-2633
        • Raggi P.
        • Boulay A.
        • Chasan-Taber S.
        • Amin N.
        • Dillon M.
        • Burke S.K.
        • Chertow G.M.
        Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease?.
        J Am Coll Cardiol. 2002; 39: 695-701
        • Goodman W.G.
        • Goldin J.
        • Kuizon B.D.
        • Yoon C.
        • Gales B.
        • Sider D.
        • Wang Y.
        • Chung J.
        • Emerick A.
        • Greaser L.
        • Elashoff R.M.
        • Salusky I.B.
        Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.
        N Engl J Med. 2000; 342: 1478-1483
        • Foley R.N.
        • Collins A.J.
        • Herzog C.A.
        • Ishani A.
        • Kalra P.A.
        Serum phosphorus levels associate with coronary atherosclerosis in young adults.
        J Am Soc Nephrol. 2009; 20: 397-404
        • Ix J.H.
        • De Boer I.H.
        • Peralta C.A.
        • Adeney K.L.
        • Duprez D.A.
        • Jenny N.S.
        • Siscovick D.S.
        • Kestenbaum B.R.
        Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA.
        Clin J Am Soc Nephrol. 2009; 4: 609-615
        • Dhingra R.
        • Gona P.
        • Benjamin E.J.
        • Wang T.J.
        • Aragam J.
        • D'Agostino Sr., R.B.
        • Kannel W.B.
        • Vasan R.S.
        Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community.
        Eur J Heart Fail. 2010; 12: 812-818
        • Saab G.
        • Whooley M.A.
        • Schiller N.B.
        • Ix J.H.
        Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study.
        Am J Kidney Dis. 2010; 56: 496-505
        • Onufrak S.J.
        • Bellasi A.
        • Shaw L.J.
        • Herzog C.A.
        • Cardarelli F.
        • Wilson P.W.
        • Vaccarino V.
        • Raggi P.
        Phosphorus levels are associated with subclinical atherosclerosis in the general population.
        Atherosclerosis. 2008; 199: 424-431
        • Block G.A.
        • Hulbert-Shearon T.E.
        • Levin N.W.
        • Port F.K.
        Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
        Am J Kidney Dis. 1998; 31: 607-617
        • Ganesh S.K.
        • Stack A.G.
        • Levin N.W.
        • Hulbert-Shearon T.
        • Port F.K.
        Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.
        J Am Soc Nephrol. 2001; 12: 2131-2138
        • Kestenbaum B.
        • Sampson J.N.
        • Rudser K.D.
        • Patterson D.J.
        • Seliger S.L.
        • Young B.
        • Sherrard D.J.
        • Andress D.L.
        Serum phosphate levels and mortality risk among people with chronic kidney disease.
        J Am Soc Nephrol. 2005; 16: 520-528
        • Dhingra R.
        • Sullivan L.M.
        • Fox C.S.
        • Wang T.J.
        • D'Agostino Sr., R.B.
        • Gaziano J.M.
        • Vasan R.S.
        Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.
        Arch Intern Med. 2007; 167: 879-885
        • Foley R.N.
        • Collins A.J.
        • Ishani A.
        • Kalra P.A.
        Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk In Communities (ARIC) study.
        Am Heart J. 2008; 156: 556-563
      1. The ARIC Investigators. The Atherosclerosis Risk In Communities (ARIC) study: design and objectives.
        Am J Epidemiol. 1989; 129: 687-702
        • National Heart, Lung and Blood Institute
        Atherosclerosis Risk In Communities (ARIC) Study: Operations Manual No. 10. Clinical Chemistry Determinations.
        National Heart, Lung and Blood Institute, Bethesda1987 (pp 1–76)
        • Portale A.A.
        • Halloran B.P.
        • Morris Jr., R.C.
        Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men.
        J Clin Invest. 1989; 83: 1494-1499
        • Watson K.E.
        • Abrolat M.L.
        • Malone L.L.
        • Hoeg J.M.
        • Doherty T.
        • Detrano R.
        • Demer L.L.
        Active serum vitamin D levels are inversely correlated with coronary calcification.
        Circulation. 1997; 96: 1755-1760
        • Zittermann A.
        • Schleithoff S.S.
        • Tenderich G.
        • Berthold H.K.
        • Korfer R.
        • Stehle P.
        Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?.
        J Am Coll Cardiol. 2003; 41: 105-112
        • Rienstra M.
        • Lubitz S.A.
        • Zhang M.L.
        • Cooper R.R.
        • Ellinor P.T.
        Elevation of parathyroid hormone levels in atrial fibrillation.
        J Am Coll Cardiol. 2011; 57: 2542-2543
        • Seiler S.
        • Cremers B.
        • Rebling N.M.
        • Hornof F.
        • Jeken J.
        • Kersting S.
        • Steimle C.
        • Ege P.
        • Fehrenz M.
        • Rogacev K.S.
        • Scheller B.
        • Bohm M.
        • Fliser D.
        • Heine G.H.
        The phosphaton in fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.
        Eur Heart J. 2011; 32: 2688-2696